Navigation Links
Golub Capital Provides Debt Financing to Support the Acquisition of DNA Diagnostics Center, Inc. by MTS Health Investors, LLC

NEW YORK, Oct. 21 /PRNewswire/ -- Golub Capital today announced that it has provided a GOLD facility for the acquisition of DNA Diagnostics Center, Inc. (DDC) by MTS Health Investors, LLC (MTS). GOLD financings are proprietary Golub Capital One-Loan Debt facilities. Terms of the transaction were not disclosed.

DDC, based in Fairfield, Ohio, is one of the largest and most reputable DNA testing laboratories worldwide and the market leader in human DNA identification testing for the private sector. The Company provides a wide array of DNA testing services in the fields of biological family relationships, forensics and veterinary genetics.

DDC has achieved national recognition serving as the laboratory of choice for many national media programs including Dateline, 48 Hours and Dr. Phil, and has provided the DNA testing for numerous high-profile legal disputes. These cases include the Ohio Innocence Project, which helped exonerate Robert McClendon after 18 years of incarceration, and the landmark paternity suit that identified Larry Birkhead as the biological father of Anna Nicole Smith's daughter.

This is Golub Capital's first deal with MTS. "We are pleased to be working with MTS," said Golub Capital Principal Stefano Robertson. "Golub Capital's financial resources will help strengthen DDC's position in its unique marketplace. We are looking forward to watching DDC grow internationally."

"In this difficult economic environment it is terrific to have Golub Capital as a partner. Golub followed through with its commitment even during this volatile credit market. After working with the Golub team on closing this deal, we are confident that Golub will help us grow the company as we capitalize on opportunities within the DNA testing industry," says Kenton Rosenberry, a Managing Director with MTS.

About Golub Capital

Golub Capital underwrites and syndicates 1st lien loans up to $150 million. Our buy-and-hold products range from $5 million to $75 million and include one-loan financings (through the Firm's proprietary GOLD facility), senior, second lien and subordinated debt, preferred stock and co-investment equity. With a broad investment mandate and long-term time horizon, Golub Capital has a high level of flexibility in structuring investments. Golub Capital is a national firm. For more information, please visit

SOURCE Golub Capital
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Simbionix Raises Largest Amount in Companys History in Venture Capital to Accelerate Growth
2. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
3. Solos Endoscopy, Inc. Implements Strategy to Capitalize on $30 Billion Minimally Invasive Surgical Product Market
4. CPC of America, Inc. to Explore Strategic Alternatives; Appoints FTI Capital Advisors to Assess Potential Opportunities
5. Aerolase Retains SMH Capital Inc. to Advise on Corporate Expansion
6. Tengion Featured as Model of Innovation and Success at 35th Anniversary Celebration of the National Venture Capital Association
7. Aegis Analytical Corp. Showcases Discoverant at Inaugural Venture Capital in the Rockies Fall
8. Sinobiomed Retains CB Capital Partners as Financial Advisor to Maximize Shareholder Value
9. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
10. TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm
11. MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments
Post Your Comments:
(Date:11/27/2015)... /PRNewswire/--  Mallinckrodt plc (NYSE: MNK ), a ... closed the sale of its global contrast media and ... in a transaction valued at approximately $270 million. The ... total of approximately 1,000 employees spread across the globe, ... area. This entire workforce and the manufacturing ...
(Date:11/26/2015)... 26, 2015 ... Accutest Research Laboratories, a leading independent ... (CRO), has formed a strategic partnership ... Temple Health for joint work on ... ) , --> ...
(Date:11/25/2015)... ANNAPOLIS, Md. , Nov. 25, 2015  PharmAthene, ... of Directors has adopted a stockholder rights plan (Rights ... its net operating loss carryforwards (NOLs) under Section 382 ... --> --> PharmAthene,s use of its ... an "ownership change" as defined in Section 382 of ...
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 ... HART ), a biotechnology company developing bioengineered organ implants ... McGorry will present at the LD Micro "Main ... 2:30 p.m. PT. The presentation will be webcast live ... Management will also be available at the conference for ...
Breaking Biology Technology:
(Date:10/26/2015)... 2015  Delta ID Inc., a company focused on ... PC devices, announced its ActiveIRIS® technology powers the iris ... launched by NTT DOCOMO, INC in Japan ... smartphone to include iris recognition technology, after a very ... in May 2015, world,s first smartphone to have this ...
(Date:10/23/2015)... GOLETA, California , October 23, 2015 ... Instruments (SMI) announce a mobile plug and play integration ... interactive real-world tasks SensoMotoric Instruments (SMI) ... established wearable solutions for eye tracking and physiological data ... with SMI Eye Tracking Glasses 2w and ...
(Date:10/22/2015)... -- Synaptics (NASDAQ: SYNA ), a leading developer of human interface ... 30, 2015. --> --> ... percent over the comparable quarter last year to $470.0 million. Net ... or $0.62 per diluted share. --> ... fiscal 2016 grew 39 percent over the prior year period to ...
Breaking Biology News(10 mins):